Type 2 Diabetes

Khunti, Prof. K., Leicester, United Kingdom The ongoing challenge of type 2 diabetes: why we still need new approaches

Fioretto, Prof. P., Padova, Italy A novel way of treating type 2 diabetes: removing excess glucose through SGLT2 inhibition

O’Neal, Dr. D., Melbourne, Australia Stepping up – why insulin therapy in people with type 2 diabetes is often initiated too late and what we need to do against it: The Australian perspective

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 2: Using FPG to safely titrate long acting basal insulin?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 8: Nutrition – any changes warranted, especially any supplementation with PUFAs?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany The ORIGIN-Trial: Conclusion

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 7: Long acting insulins firstline therapy: What are the risks?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 6: Screening for IGT?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 5: Targeting FPG vs postprandial glucose?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 4: Specific benefits of early insulinisation?

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 3: Long acting insulins firstline therapy versus other established options

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany Question 1: Targets of glycemic control

Standl, Prof. E., Munich, Germany / Hanefeld, Prof. M., Dresden, Germany The ORIGIN-Trial

Schnell, Prof. O., Munich, Germany Self-monitoring of blood glucose: Impact on CV risk in diabetes

Gallwitz, Prof. J. B., Tuebingen, Germany Linagliptin: a new alternative in DPP-4 inhibition

Ceriello, Prof. A., Barcelona, Spain The need for individualized medicine in diabetes

Standl, Prof. E., Munich, Germany Statin and RAAS inhibitor for every diabetic patient?

Wilding, Prof. J., Liverpool, United Kingdom Sleep-disordered breathing and cardio-metabolic disease

Jacob, Prof. S., Villlingen-Schwenningen, Germany Saxagliptin: now and beyond

Vora, Prof. J., Liverpool, United Kingdom Case presentation and interactive discussion

Del Prato, Prof. S., Pisa, Italy Overcoming barriers now in successful treatment of type 2 diabetes

Groop, Prof. P.-H., Helsinki, Finland Impact of declining renal function on treatment choice in diabetes

Aronson, Dr. R., Toronto, Canada Setting a course for the future

Holst, Prof. J. J., Copenhagen, Denmark Going beyond conventional therapies: an update on DPP-4 inhibition

Barnett, Prof. A., Birmingham, United Kingdom A different DPP-4 inhibitor

Ceriello, Prof. A., Barcelona, Spain New clinical challenges and new opportunities: recent developments in type 2 diabetes in perspective

Raposo, Prof. J. F., Lissabon, Portugal The diabetes pandemic: a Portuguese perspective

Vora, Prof. J., Liverpool, United Kingdom Case presentation and interactive discussion

Jacob, Prof. S., Villlingen-Schwenningen, Germany New data on the emerging role of saxagliptin in type 2 diabetes

Del Prato, Prof. S., Pisa, Italy Why we should be treating to succeed

de Pablos, Prof. Pedro, Gran Canaria, Spain A review of treatment satisfaction and quality of life in people with type 2 diabetes

Holst, Prof. J. J., Copenhagen, Denmark Latest insights on incretin-based treatments

Ceriello, Prof. A., Barcelona, Spain Reducing daily glucose peaks and valleys for comprehensive glycaemic control: a clinical perspective

Avignon, Prof. A., Montpellier, France Is there a place for obstructive sleep apnoea screening in the Diabetes Clinic?

Polonsky, MD W. H., San Diego, United States Structured SMBG: Improved Glycemic Control in NIT T2D Patients - Final Results of the STeP Study

Fisher, PhD L., University of California, San Francisco, United States Structured SMBG: Study Rationale and Design of the STeP Study

Trovati, Prof. M., Turin, Italy Structured SMBG in NIT T2D Patients: The European Perspective

Standl, Prof. E., Munich, Germany Cardio-metabolic interactions and side effects of multifactorial risk management

Standl, Prof. E., Munich, Germany Cardio-metabolic interactions and side effects of multifactorial risk management

Standl, Prof. E., Vilsbøll, Dr. T., Nauck, Prof., M., Netherlands Discussion(Archiv) 18-Sep-07